Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001357550 XXXXXXXX LIVE 3 Ordinary Share $0.00001 Par Value 03/23/2026 false 0001583107 G8807B106 Theravance Biopharma, Inc. Ugland House, South Church Street George Town E9 KY1-1104 Weiss Asset Management LP (617) 778-7775 c/o Mary Merrigan 222 Berkeley St., 16th Floor Boston MA 02116 0001357550 N Weiss Asset Management LP WC N DE 0 7457060 0 7457060 7457060 N 14.5 IA PN Row 8, 10, 11, and 13: Please see Item 5. 0001298983 N BIP GP LLC WC N DE 0 4628074 0 4628074 4628074 N 9.0 HC OO Row 8, 10, 11, and 13: Please see Item 5. 0001504664 N WAM GP LLC WC N DE 0 7457060 0 7457060 7457060 N 14.5 HC OO Row 8, 10, 11, and 13: Please see Item 5. 0001357643 N Andrew M. Weiss WC N X1 0 7457060 0 7457060 7457060 N 14.5 HC IN Row 8, 10, 11, and 13: Please see Item 5. Ordinary Share $0.00001 Par Value Theravance Biopharma, Inc. Ugland House, South Church Street George Town E9 KY1-1104 This Amendment No. 3 (this "Amendment") to Schedule 13D amends the Schedule 13D initially filed on April 12, 2023, (as amended prior to the date hereof, the "Prior Schedule 13D" and, as so amended by this Amendment, the "Schedule 13D") with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D. Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The percentages set forth above have been calculated based on 51,492,924 shares of the Issuer's Shares issued and outstanding as of February 28, 2026, as reported in the Issuer's Form 10-K, filed with the SEC on March 23, 2026. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D/A shall not be deemed an admission of beneficial ownership of any Shares for any purpose. 4,628,074 Shares, representing approximately 9.0% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. 2,828,986 Shares, representing approximately 5.5% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. See cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons. See Item 5 (a). The Reporting Persons did not effect any transactions in the Issuer's Shares during the past 60 days. Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares. Not applicable. Weiss Asset Management LP Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 03/25/2026 BIP GP LLC Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 03/25/2026 WAM GP LLC Mary Merrigan MARY MERRIGAN, AUTHORIZED SIGNATORY 03/25/2026 Andrew M. Weiss Mary Merrigan MARY MERRIGAN, ATTORNEY-IN-FACT FOR ANDREW M. WEISS*** 03/25/2026 *** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on February 3, 2023 in respect of its holding in DEEP MEDICINE ACQUISITION CORP.